Search
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]
Nitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179824] Nitrofurantoin is a second line treatment to [trimethoprim]/[sulfamethoxazole].[A179830] Nitrofurantoin was granted FDA approval on 6 February 1953.[L6895] … [A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once.
Synonyms: N-(5-Nitrofurfurylidene)-1-aminohydantoinETC-588
go.drugbank.com/drugs/DB05456Experimentaland other lipids from cells including those in the arterial wall. … It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis.
Tetrachlorodecaoxide
go.drugbank.com/drugs/DB05389ApprovedThe Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer. … WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers.
Categories: Compounds used in a research, industrial, or household settingNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. … [L43277] Niraparib is selective towards PARP-1 and PARP-2.
Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256 … The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255].
Categories: Drugs Used in Diabetes, DPP-IV InhibitorsFebuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalThe manufacturer and the FDA advise health professionals to limit the use of febuxostat to second-line therapy in patients who have inadequate response or intolerance to allopurinol, and to avoid the use … [A230548] In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate response or intolerance to [allopurinol
Bordetella pertussis toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14388ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer FertigspritzeTeplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigationalTeplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients
Categories: Drugs Used in DiabetesMesalazine
go.drugbank.com/drugs/DB00244ApprovedInvestigationalthe risk of colorectal cancer in conditions like ulcerative colitis is maintained. … An anti-inflammatory agent, structurally related to the salicylates and non-steroidal anti-inflammatory drugs like acetylsalicylic acid, which is active in inflammatory bowel disease [A174022].